Abstract:To investigate response and survival of radiotherapy (RT) for hepatocellular carcinoma with tumor thrombosis in main portal vein or vena cava, and to analyze prognostic factors. From January 2010 to December 2016, a total of 61 cases of hepatocellular carcinoma with pathological or clinical diagnosis of hepatocellular carcinoma with tumor thrombosis in main portal vein or vena cava were enrolled this study. Main portal vein tumor thrombosis (PVTT) was defined as tumor thrombi was located in main trunk or first branches of portal vein. Fifty-five patients were with PVTT and 4 patients were with venous vein tumor thrombosis alone, respectively. In addition, another 2 patients were with both vein thromboses. All patients had a liver function of Child-Pugh A before radiotherapy. Eighty-five percent of patients (52/61) had a history of hepatitis B, 2% (2/61) had hepatitis C, and 12% (7/61) had no history of hepatitis. Eighty-four percent of patients (51/61) had previously received transcatheter arterial chemoembolization (TACE). Eight patients were treated with concurrent RT and sorafenib. Tumor response was evaluated in one to three months after completion of RT. Survival and prognostic factors were analyzed by Kaplan-Meier method and Cox regression model. The factors included gender, age, history of hepatitis, AFP level before radiotherapy, number of intrahepatic lesions, maximum tumor diameter (MTD), combined TACE, radiotherapy dose were included in analysis of prognosis. All patients were treated with intensity modulated radiotherapy by conventional fraction of 2Gy/f. The median dose was 50Gy (28-66Gy). Response rate (RR, complete response + partial response) was 55.7% when considering all lesions of whole body. In field of RT, RR of the primary tumor was 77.1% and RR of the tumor thrombosis was 83.7%. The 2-year overall survival was 29.9% and median survival time (MST) was 13.6 months. Median time to progression (TTP) was 4.7 months. The 2-year progression free survival of tumor thrombosis was 88.6%. Multivariate analysis showed that the MTD>10cm was an independent poor prognostic factor of TTP (HR, 1.961, 95%CI, 1.034-3.717). TTP in patients with MTD≤10cm and MTD>10cm were 5.0 months and 3.3 months (p=0.026), respectively. However, for MST, combination of TACE (both before or after RT) was an independent favor prognostic factor (HR, 0.184, 95%CI, 0.06-0.565). MST of combination therapy was 15 months, and MST of patients receiving radiotherapy alone was 4 months (p<0.001). Of all patients, grade III or higher liver function damage was 1.6%, and no lethal radiation-induced liver disease occurred. Grade III or higher hematological toxicity was 11.5%. The tumor thrombosis is more sensitive to radiation therapy than the primary tumor. Radiotherapy improves survival by the perfect control of tumor thrombosis. Progression of outside field of RT is primary failure mode for patients with main PVTT. Combination of radiotherapy and TACE is benefit to survivals.

Determinants of Survival of Ablation Treatment for Portal Vein Tumor Thrombus in Patients With Hepatocellular Carcinoma

Evaluating the long-term survival benefits of high intensity focused ultrasound ablation for hepatocellular carcinoma with portal vein tumor thrombus: a single center retrospective study

Chemotherapeutic Perfusion of Portal Vein after Tumor Thrombectomy and Hepatectomy Benefits Patients with Advanced Hepatocellular Carcinoma: A Propensity Score‐matched Survival Analysis

Efficacy And Prognosis Of Radiotherapy For Hepatocellular Carcinoma With Tumor Thrombosis In Main Portal Vein Or/And Vena Cava

Survival benefit of neoadjuvant hepatic arterial infusion chemotherapy followed by hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus

The efficacy and safety of postoperative adjuvant transarterial embolization and radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombus.

Efficacy of Different Treatment Strategies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

Similar Efficacy Between Atezolizumab Plus Bevacizumab Versus Hepatic Arterial Infusion Chemotherapy For Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Cohort Study

Postoperative Adjuvant Trans-Arterial Chemoembolization for Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus

[Hepatic Resection with Removal of Tumor Thrombi for Hepatocellular Carcinoma with Tumor Thrombi in Portal Vein and Curative Analysis].

Development of a Prognostic Scoring System for Hepatocellular Carcinoma Patients With Main Portal Vein Tumor Thrombus Undergoing Conventional Transarterial Chemoembolization: An Analysis of 173 Patients

Transarterial Chemoembolization Combined With Endoscopic Therapy Is Beneficial for Unresectable Hepatocellular Carcinoma With Esophagogastric Varices

Efficacy of Liver-Directed Combined Radiotherapy in Locally Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis.

Preoperative Stereotactic Body Radiotherapy to Portal Vein Tumour Thrombus in Hepatocellular Carcinoma: Clinical and Pathological Analysis

Efficacy comparison of optimal treatments for hepatocellular carcinoma patients with portal vein tumor thrombus

Neoadjuvant-Based Triple Therapy for Hepatocellular Carcinoma with Type I/II Portal Vein Tumor Thrombosis

Treatment of Hepatocellular Carcinoma-associated Portal Vein Tumor Thrombus Using Combination of Portal Vein Stent Insertion and Endovascular Lodine-125 Seed-strip Implantation Followed by Transcatheter Arterial Chemoembolization- Sorafenib

Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: a Meta-Analysis

Radiotherapy with targeted and immunotherapy improved overall survival and progression-free survival for hepatocellular carcinoma with portal vein tumor thrombosis

[Time Dependency of Factors Influencing Survival of Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis after Surgery].

Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study.